Following the signature of a multi-year large scale
peptide
manufacturing
agreement earlier this year,
CordenPharma
is pleased to announce the inauguration of
increased
commercial
peptide
production
capacity with newly-upgraded facilities at
CordenPharma
Colorado, the
largest
Solid-Phase
Peptide
Synthesis (
SPPS
)
Manufacturing
facility
worldwide
.
After kicking off capital investments in early 2023,
CordenPharma
successfully completed a series of upgrades and modernizations to the facility which have
increased
the efficiency and throughput of
SPPS
peptide
production
, allowing for
increased
capacity to service current and future customers across a
growing
pharmaceutical innovator base.
The extensive Capital Expenditure initiative includes:
Upgrades to their existing 10’000 L reactor volume with a batch size exceeding 400 kg (> 35 Amino Acids), and a yearly capacity of > 2 Metric Tons of
Peptide
A 50% increase in downstream HPLC purification capacity • Automation upgrades that allow a reduction in overall cycle time, greater scale-up consistency, and the elimination of human error
Implementation of PAT for amino acid identification to avoid errors in
peptide
sequence, and ready-to-use process intensification with continuous washing and reaction monitoring
Modernization of critical infrastructure for
increased
efficiency of solvent delivery (> 150’000 L) and effluent removal, including the strategic alignment of the deprotection (up to 20′ 000 L capacity), cleavage and isolation of crude
peptide
with the
increased
SPPS
reactor capacity.
With decades of proven
SPPS
production
,
CordenPharma
Colorado is pleased to expand their team of experts to accommodate the overall capacity increase and resulting project
demand
. On top of its existing workforce of > 500 employees, they expect to add another 60 employees, with additional staff in the future as needed.
As a continuation of
CordenPharma
’s 2023 investment strategy across all technology platforms including peptides, the updates of the world’s
largest
SPPS
peptide
capacity perfectly complements
CordenPharma
’s robust end-to-end service offerings with fully-integrated sterile injectable capabilities in
CordenPharma
Caponago (IT), including recently-expanded LNP Formulation and Fill & Finish capacity.
Dr. Michael Quirmbach,
CordenPharma
’s CEO commented: “This expansion marks another milestone for
CordenPharma
, cementing our position as the leading large-scale
Peptide
CDMO partner to the pharmaceutical and biotech industry. Under the leadership of Brian McCudden, I am very proud of our team in Colorado for their great implementation of this challenging project on time and within budget.”
Dr. Stéphane Varray,
CordenPharma
’s Global
Peptide
Platform Director, added: “
CordenPharma
is pleased to celebrate the start of
peptide
production
in our newly-upgraded and expanded
SPPS
manufacturing
facility in Colorado with the
largest
worldwide
peptide
capacity available. These modernizations will allow for
increased
efficiency, throughput, and access to state-of-the-art technologies for streamlined commercial
peptide
API supply.
Our team at
CordenPharma
Colorado brings unparalleled expertise in proven
peptide
production
across all scales and phases, which is fully-integrated with our flexible sterile injectable capabilities. We look forward to supporting an expanding base of pharmaceutical innovators with bespoke
peptide
supply tailored to support the complex modalities of their therapeutic drug development and commercialization journey.”
content
See Full Bio
